Edward Bartles on Future of Clinical Trials: IQVIA

 

The Future of Clinical Trials: Integrating Technology and patient Experience

In this engaging interview, Edward Bartles, Associate Director of Solution Engineering at IQVIA, discusses the impact of digital health technologies and wearables on the clinical trials landscape. The conversation covers IQVIA’s strategic approach to embedding digital tools in the research process—from electronic clinical outcome assessments (eCOA) and IoT platforms to global device sourcing and real-time data collection. Edward explains how adopting e-consenting, connected devices, and flexible trial design reduces patient burden and improves engagement across multi-region Phase III studies.
https://www.youtube.com/watch?v=S0nhMq5eils&t=39s
Special emphasis is given to regulatory trends, including decentralized trial implementation, EU clinical trials regulation, and the increasing flexibility behind trial methodology. The discussion highlights the importance of ensuring data quality, adaptability, and enhancing both the patient experience and clinical outcomes through innovative technology. Real-world examples showcase how integrating wearables efficiently sources data, improves patient support, and meets regulatory requirements, ultimately advancing pharma research.

Watch as industry expert Edward Bartles explores how clinical trials are rapidly evolving. Learn how digital health integration, wearable tech, and patient-centric innovation are shaping the future of clinical research. Discover practical insights into regulatory adaptation, improving patient engagement, and leveraging smart devices for superior trial outcomes. Edward Bartles of IQVIA shares how digital health, wearables, and eCOA are transforming clinical trials. Explore patient-centric innovation, regulatory trends, For info visit us https://www.worldpharmatoday.com/ , For more info: sunny@worldpharmatoday.com

Location: Hyderabad, Telangana, India

Comments

Post a Comment

Popular posts from this blog

CPHI & PMEC China Sees Surge in International Attendance as Global Pharma Trade Outlook Strengthens

  CPHI & PMEC China (June 24-26 th ) returns to the Shanghai New International Expo Center amid a marked surge in international interest, with industry momentum rebounding following a string of positive developments in global trade and pharmaceutical investment. The 2025 edition is set to become the largest pharma event ever held in Asia, with more than 90,000 attendees and over 12,000 international executives expected. The recent trade tariff reprieve[1], alongside an improving global outlook for pharma – i.e. higher valuations and improved capital expenditure by biotech and big pharma – is transforming into greater international interest at CPHI & PMEC China. International executives will visit the event in record numbers as pharma companies look for new ingredient suppliers and equipment providers. Another key trend emerging is the increasing interest from global pharmaceutical companies in Chinese biotech assets – not only for access to the domestic market, but als...
Read more

Syntegon Reports Accelerated Growth in 2024 Results

  Syntegon delivers record results in 2024 New strategy fuels accelerated growth following CEO transition in late 2023 Order intake increased by 11% to 1.8 billion EUR and revenue grew by 7% to 6 billion EUR Strong EBITDA improvement by 15% to 222 million EUR and 14% EBITDA margin (up 100 bps) Focused cash flow generation program delivers strong improvement Strategic focus on turnkey solutions for the global Pharmaceutical and Biotech industries Accelerated growth and further results improvement targeted in 2025 Waiblingen, May 15, 2025 – The Syntegon Group, a leading strategic partner to the global pharmaceutical, biotech and food industries, reported record results for fiscal year 2024. Driven by its newly introduced corporate strategy focused on growth, operational excellence and long-term value creation, Syntegon achieved accelerated growth, strong profitability, and improved cash flow. Strategic initiatives launched in 2024 included targeted investments in portfolio expansion ...
Read more

Particulate Matter in Injectables: Risks and Controls

Image
  Based on available data from US FDA between Aug 2017 to Feb 2024, approximately 31% of injectable drug recalls were due to the presence of particulates contamination [1]. Even as improvement measures are being adopted by the pharmaceutical manufacturers to reduce the occurrence of particulate-related recalls, the issue of particulates in drugs continues to be an important topic that is scrutinized by US FDA. In December 2021, US FDA further introduced a draft guidance for industry ‘Inspection of Injectable Products for Visible Particulates’, which emphasizes the importance of using ‘a holistic, risk-based approach to visible particulate control that incorporates product development, manufacturing controls, visual inspection techniques, particulate identification, investigation, and corrective actions designed to assess, correct, and prevent the risk of visible particulate contamination’. Although the United States Pharmacopeial (USP) General Chapters, such as USP <787>, ...
Read more